Gadobenic acid
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C22H28GdN3O11 |
Molar mass | 667.72 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Gadobenic acid |
Articles |
---|
Most recent articles on Gadobenic acid Most cited articles on Gadobenic acid |
Media |
Powerpoint slides on Gadobenic acid |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Gadobenic acid at Clinical Trials.gov Trial results on Gadobenic acid Clinical Trials on Gadobenic acid at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Gadobenic acid NICE Guidance on Gadobenic acid
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Gadobenic acid Discussion groups on Gadobenic acid Patient Handouts on Gadobenic acid Directions to Hospitals Treating Gadobenic acid Risk calculators and risk factors for Gadobenic acid
|
Healthcare Provider Resources |
Causes & Risk Factors for Gadobenic acid |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Gadobenic acid (tradename MultiHance) is a complex of gadolinium with the ligand BOPTA. In the form of the diglumine salt it functions as a gadolinium-based MRI contrast medium, under the trade name gadobenate dimeglumine.
BOPTA is a derivative of DTPA in which one terminal carboxyl group, –C(O)OH is replaced by -C–O–CH2C6H5. Thus gadobenic acid is closely related to gadopentetic acid. BOPTA itself was first synthesized in 1995. [1] In the "gadobenate" ion gadolinium ion is 9-coordinate with BOPTA acting as an 8-coordinating ligand. The ninth position is occupied by a water molecule, which exchanges rapidly with water molecules in the immediate vicinity of the strongly paramagnetic complex, providing a mechanism for MRI contrast enhancement. 139La NMR studies on the diamagnetic La-BOPTA2− complex suggest that the Gd complex maintains in solution the same kind of coordination as found, by X-ray crystallography, in the solid state for Gd-BOPTA disodium salt.[1]
- ↑ 1.0 1.1 Uggeri, F.; Aime, S., Anelli, P.L., Botta, M., Brocchetta, M., De Haën, C., Ermondi, G., Grandi, M., Paoli, P. (1995). "Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln = Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8, 11-triazatridecan-13-oato(5-)]gadolinate(2-) in a mixture with its enantiomer". Inorg. Chem. 34 (3): 633–642. doi:10.1021/ic00107a017.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Articles with changed CASNo identifier
- Articles with changed ChemSpider identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles with changed InChI identifier
- Chemical articles with unknown parameter in Infobox drug
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drug